The combination of modular facilities and closed processing offers significant advantages in the production of biopharmaceuticals and is becoming a compelling option for manufacturing.
JP Bornholdt
Advertisement
JP Bornholdt is director, SlateXpace Technical Operations at CRB.
Articles by JP Bornholdt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
3
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5